Researches and discovers treatments for psychiatric disorders. Researches and discovers treatments for neurological disorders. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $55.2M in the vault; even if every debt were paid off, $55.2M would remain.
Over the last 12 months, company executives reported 37 buys and 3 sells. Management buying with its own money is usually read as a good sign.
A loss of $20.4M against $0 in annual sales.
The stock sits at $0.0028. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.